Diagnostic method for neurodegenerative diseases based on measurement of SIRT1 levels or activity

(19)

(11)

EP 2 362 226 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	06.04.2016 Bulletin 2016/14

(45)	Mention of the grant of the patent:
	17.02.2016 Bulletin 2016/07

(21)	Application number: 10187871.8

(22)	Date of filing: 07.03.2006

(51)

International Patent Classification (IPC):

G01N 33/68^(2006.01)
A61P 25/28^(2006.01)

C12Q 1/34^(2006.01)

(54)

Diagnostic method for neurodegenerative diseases based on measurement of SIRT1 levels or activity

Diagnostisches Verfahren für neurodegenerative Krankheiten basierend auf der Messung von SIRT1 Spiegel oder Aktivität

Méthode diagnostique pour maladies neurodégénératives basée sur la mesure des niveaux ou de l'activité de SIRT1

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30)

Priority:

07.03.2005 US 74374

(43)	Date of publication of application:
	31.08.2011 Bulletin 2011/35

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	06737459.5 / 1863461

(73)	Proprietors:
	President and Fellows of Harvard College Cambridge, MA 02138 (US) Biomol International L.P. Plymouth Meeting, PA 19462-1202 (US)

(72)	Inventors:
	Sinclair, David Chestnut Hill, MA 02467 (US) Tsai, Li-huei Cambridge, Massachusetts 02138 (US) Nguyen, Minh Calgary, Alberta T2P 5P6 (US) Howitz, Konrad Allentown, Pennsylvania 18104 (US) Zipkin, Robert Wynnewood, Pennsylvania 19096 (US) Bitterman, Kevin J. Boston, MA 02118 (US)

(74)	Representative: Lee, Nicholas John et al
	Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ London WC1R 4PJ (GB)

(56)

References cited: :

WO-A-2005/002555

WO-A2-2006/068656

PORCU M ET AL: "The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 26, no. 2, 1 February 2005 (2005-02-01), pages 94-103, XP004727629, ISSN: 0165-6147, DOI: DOI:10.1016/J.TIPS.2004.12.009
ARAKI T ET AL: "Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 305, 13 August 2004 (2004-08-13), pages 1010-1013, XP003001697, ISSN: 0036-8075, DOI: DOI:10.1126/SCIENCE.1098014

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).